Epstein-Barr virus antigen-derived peptide-HLA complex (EBV pHLA) (EBV pHLA)

The Epstein-Barr virus (EBV) antigen-derived peptide-HLA complex is a critical immunological target presented on the surface of EBV-infected B cells and associated neoplastic lesions, such as those in post-transplant lymphoproliferative disorder (PTLD). These complexes are formed when viral proteins—either from the latent phase (e.g., EBNA1, LMP1, LMP2) or the lytic phase (e.g., BZLF1)—are processed into short peptides and loaded onto Human Leukocyte Antigen (HLA) molecules for presentation to the immune system (PMID: 31435474). They function as the specific ligands for T-cell receptors (TCRs) on CD8+ cytotoxic T lymphocytes, which are responsible for identifying and eliminating virally infected or transformed cells (PMID: 25635017). In therapeutic applications, these complexes are targeted by adoptive cell therapies, including EBV-specific T-cells (EBVSTs) and TCR-engineered T-cells, to treat EBV-associated malignancies (PMID: 36516543). The most prominent example is tabelecleucel, an allogeneic T-cell therapy designed to recognize these complexes in patients with relapsed or refractory EBV+ PTLD (PMID: 36516543). By targeting these specific viral antigens, the therapy aims to selectively kill tumor cells while sparing healthy tissue, addressing a significant unmet need in immunocompromised patients. This targeting strategy is highly dependent on the patient's HLA type, as the T-cell product must match the specific HLA molecule presenting the viral peptide. Overall, the EBV pHLA complex represents a cornerstone of precision immunotherapy for virus-driven cancers.

Other names

EBV pMHCEBV peptide-MHC complexEBV-specific HLA-peptide complexEBV latent antigen-HLA complexEBV lytic antigen-HLA complexEBV-peptide-MHC class I complex

Recognition of the peptide-HLA complex by specific T-cell receptors (TCRs) on cytotoxic T-lymphocytes, triggering directed cell lysis and cytokine release against EBV-infected cells.